New frontiers in radioembolization

Arian Mansur (ID), Peiman Habibollahi, Adam Fang, Armeen Mahvash, Vahid Etezadi, Robert P. Liddell, Juan C. Camacho, Emil I. Cohen, Nima Kokabi, Aravind Arepally, Christos Georgiades and Nariman Nezami

Abstract: Radioembolization is a locoregional transarterial therapy that combines radionuclide and micron-sized beads to deliver radiation internally to the target tumors based on the arterial blood flow. While initially developed as a palliative treatment option, radioembolization is now used for curative intent treatment, neoadjuvant therapy, and method to downstage or bridge for liver transplant. Radioembolization has become increasingly utilized and is an important therapeutic option for the management of hepatocellular carcinoma and liver metastasis. This article provides an overview of the techniques, challenges, and novel developments in radioembolization, including new dosimetry techniques, radionuclides, and new target tumors.

Keywords: radioembolization, selective internal radiation therapy, dosimetry, eye90, holmium

Brief history of radioembolization

Radiation therapy involves the use of particles or electromagnetic waves to induce damage to cancer cells.[1,2] Ionizing radiation, which forms sufficient particle energy, can be divided into either photon radiation (e.g., X-rays and gamma rays) or particle radiation (e.g., electron, proton, neutron, carbon ions, alpha particles, and beta particles).[3] Both forms of radiation can be used for imaging and treating cancer. Radiation therapy can be delivered either by external beam radiation therapy (i.e., local treatment by an extracorporeal machine), internal radiation therapy (i.e., intracorporeal radiation source), and radiopharmaceuticals (i.e., systemic treatment with drugs that contain radioisotopes).[4,5] When internal radiation therapy is done with a solid source, such as a seed, ribbon, or capsule, it is termed brachytherapy. Brachytherapy with beta particles has revolutionized the treatment of liver cancer.

Transarterial radioembolization (TARE), also known as selective internal radiation therapy (SIRT), is a locoregional therapy that involves transarterial administration of micron-sized beads (microspheres) that carry radioactive isotopes to block a small portion of the blood supply and deliver highly targeted doses of radiation to tumors.[6] It was first developed as a palliative option for patients with unresectable liver tumors, but it is now increasingly utilized with curative intent. TARE is effective for treating liver cancer because of the liver's dual blood supply. As liver tumors grow, their perfusion becomes dependent on the hepatic artery, while the liver is perfused primarily by the portal vein, enabling tumor-targeted therapy[7] with minimal collateral damage. TARE treatment for hepatocellular carcinoma (HCC) can increase the time to tumor progression, induce hypertrophy of the liver remnant, and/or downstage or bridge patients for transplantation or resection.[6,8,9] Yttrium-90 (^{90}Y) is the radioactive isotope most commonly used with TARE. Compared with other techniques, such as surgery or ablation, radioembolization is more flexible with regard to the site and number of tumors treated.[10]

Several clinical trials have reported the effective use of microspheres to deliver targeted radiation to liver tumors.[11,12] There are also several ongoing clinical trials investigating the role of TARE for cancer patients, especially in the setting of systematic therapy.[13] Two manufactured microspheres are commercially available for clinical use: glass beads (TheraSphere®, BTG International Ltd,

Correspondence to:
Nariman Nezami
Division of Vascular and Interventional Radiology, Department of Radiology, Georgetown University School of Medicine, 3800 Reservoir Road, NW, CCC Bldg., Room CG225, Washington, DC 20007, USA
dr.nezami@gmail.com

Arian Mansur
Harvard Medical School, Boston, MA, USA

Peiman Habibollahi
Armeen Mahvash
Division of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Adam Fang
Vahid Etezadi
Division of Vascular and Interventional Radiology, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

Robert P. Liddell
Christos Georgiades
Division of Vascular and Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Juan C. Camacho
Department of Clinical Sciences, College of Medicine, Florida State University, Tallahassee, FL, USA

Vascular and Interventional Radiology, Radiology Associates of Florida, Sarasota, FL, USA

Emil I. Cohen
Division of Vascular and

Interventional Radiology,
Department of Radiology,
Georgetown University
School of Medicine,
Washington, DC, USA

Nima Kokabi
Department of Radiology,
University of North
Carolina at Chapel Hill,
Chapel Hill, NC, USA

Aravind Arepally
Radiology Associates of
Atlanta, Atlanta, GA, USA

ABK Biomedical Inc.,
Atlanta, GA, USA

London, UK) and resin beads (SIR-Spheres®, SirTex Medical, Sydney, NSW, Australia).[10,14,15] TheraSphere was approved by the Food and Drug Administration's (FDA) under the Humanitarian Device Exemption provision for unresectable HCC in 1999 and was given full premarketing approval in 2021. SIR-Spheres was given approval 2002 to treat colorectal cancer with liver metastasis in conjunction with adjuvant floxuridine chemotherapy.[16] Glass beads (20–30 microns in diameter) are slightly smaller than resin beads (mean of 32 microns in diameter) and produce a lower degree of embolization and in most clinical practice deliver a higher activity per particle (Glass: 2500 Bq per microsphere; Resin: 50 Bq per microsphere[17]).[10,18–21] However, with the advent of flexible daily dosing adjustments, the activity of individual resin microspheres can vary depending on the day of calibration but does not generally exceed activity per particle when compared to glass (4000 Bq max). Similarly, offering different activities of Yttrium-90 (^{90}Y) glass beads within a 2-week range can provide flexibility in treatment planning by varying the number of microspheres per vial and their activity levels. By adjusting the number of microspheres and their activity, clinicians can optimize the radiation dose distribution within the liver, enhancing the effectiveness of the treatment while minimizing side effects.

Radioembolization for HCC

TARE may be considered for solitary HCC ≤ 8 cm, given the findings from the LEGACY trial.[22] For patients with Barcelona clinic liver cancer (BCLC) stage A or B, radiation lobectomy via TARE may be considered in some patients in order to increase remnant liver volume, especially as a bridge to resection.[23] For patients who are not candidates for liver transplant, resection, or ablation, TARE may be considered if the patient meets the inclusion criteria from the LEGACY trial. However, TARE is not mentioned for patients with BCLC stage B. Finally, despite their use in real-life clinical scenarios, TARE is not included as an evidence-based recommendation for BCLC stage C patients because of negative results from prospective phase III trials.[24–27] However, these studies used outdated methodologies.

According to the European Society for Medical Oncology (ESMO), radioembolization is not indicated as first-line therapy in patients with HCC who have intermediate or advanced stages.

However, phase III studies have shown that TARE was associated with higher response rates, delayed progression of disease, and fewer adverse events when compared with sorafenib despite being negative trials.[28,29] Retrospective cohort studies have demonstrated comparable survival rates to transarterial chemoembolization (TACE) and sorafenib.[30–32] ESMO, therefore, recommends TARE for patients in "exceptional circumstances" or patients who have liver-confined disease with preserved liver function for which TACE and systemic therapy are not feasible.[33] ESMO also considers TARE instead of TACE for treating small liver tumors in patients who are waiting for liver transplants in order to avoid drop-out because of disease progression.[33] Moreover, TRACE was a phase II trial of 72 patients with unresectable HCC that showed a significantly higher survival in median overall survival for TARE over drug eluting beads TACE (DEB-TACE) (30.2 vs 15.6 months, $p = 0.006$).[34] The National Comprehensive Cancer Network (NCCN) acknowledges the use of radioembolization in some patients with advanced HCC with liver-confined or limited extrahepatic disease and recommends a tumor dose of >205 Gy or >400 Gy if selective.[35]

There have been several studies comparing TARE to ablation and surgery. A 2022 systematic review and network meta-analysis evaluated 24 randomized controlled trials and propensity score-matched cohort analyses with 5549 patients with HCC to compare radioembolization, ablation, TACE, and radiation.[36] The study found that 1-year overall survival was greater for radioembolization than TACE but no significant difference was seen in the other 1-year overall survival comparisons or in the 2- and 3-year survival comparisons (except radiation over ablation at 3-year).[36] Other studies have suggested that radiation segmentectomy has similar outcomes and may be more cost-efficient than ablation with or without TACE for small <2 cm HCC.[37] The RASER study was a single-center, single-arm study of 29 patients with unresectable ≤3 cm Child–Pugh score A-B7, ECOG 0, HCC who underwent radiation segmentectomy and were deemed unfavorable to undergo ablation.[38] The study showed a complete response in 24 (83%) patients and a partial response in 5 (17%).[38] With regard to surgery, while it is generally recommended that small HCCs that are resectable undergo surgery, the management of large ≥5 cm tends to be unclear and associated with poor postsurgical outcomes.[39]

In a 2022 retrospective cohort study, 500 patients who underwent resection were compared to 57 patients who underwent TARE for single nodular ≥5 cm HCC at 2 tertiary centers in Korea.[40] The study found comparable results in overall survival, time to progression, and time to intrahepatic progression but a shorter hospital stay and fewer adverse events in the TARE arm.[40]

Given that TARE delivers intense radiation to hepatic tumors with small embolic effects, radiologic and pathologic of TARE tend to be unique when compared with chemotherapy or TACE. Interval changes in size, tumor burden, and diffusion restriction are helpful to evaluate.[41,42] It can take several months after TARE to see a radiographic response and typically show reduced size and decreased enhancement. Additional post-treatment findings, including peritumoral edema, inflammation, ring enhancement, fibrosis, and capsular retraction, may make it harder to interpret; however, these findings are not usually signs of tumor progression.[41,42] Pathologic changes in the tumor bed after TARE include necrosis, mucinous changes, the presence of foamy histiocytes, ectatic vessels, calcification, and fibrosis.[43]

Radioembolization for metastatic colorectal cancer

While combination chemotherapy and biologics have improved the survival for patients with metastatic colorectal cancer to the liver, these therapies are very difficult to endure and about a third of patients discontinue them before finishing an entire cycle.[44,45] TARE offers a promising alternative that has been shown to be effective and well tolerated, but most of the data are limited to retrospective, single-center studies, and the exact patient population to receive the most benefit with TARE is still being determined.[46]

According to the NCCN guidelines for metastatic disease, TARE may be considered for hepatic metastatic colorectal cancer that is not resectable due to insufficient remnant liver volume. It may also be considered in selective patients with colorectal cancer with predominant hepatic metastases and whose disease is chemotherapy-resistant or chemotherapy-refractory.[47] ESMO recommends ^{90}Y radioembolization for patients with metastatic colorectal cancer, who have liver-limited disease that is unresponsive to any available chemotherapeutic options.[48]

A recent study from the multicenter and prospective Radiation-Emitting SIR-Spheres in Non-Resectable (RESiN) liver tumor patient registry elucidated the role of TARE in treating liver-dominant metastatic colorectal cancer with regard to the ideal timing and patient characteristics that would lead to improved outcomes and safety.[49] The study, which consisted of 42 centers and 498 patients, investigated TARE as first-line therapy in 17% of patients, second-line therapy in 41% of patients, and third-line therapy or beyond (salvage) in 43% of patients. The study found a median overall survival of 15 months (95% CI: 13.3–16.9) for the entire cohort, and survival was statistically different based on the line of therapy (13.9 months for first-line therapy, 17.4 months for second-line therapy, and 12.5 months for third-line therapy, $p = 0.002$). Progression-free survival (PFS) was 7.4 months (95% CI: 6.4–9.5) in the entire cohort and significantly differed based on the line of therapy (7.9 months for first-line therapy, 10 months for second-line therapy, and 5.9 months for third-line therapy, $p = 0.004$). The study also found promising safety profiles with grade 3 or greater hepatic function toxicity rates less than 10%. These findings suggest that TARE may be more beneficial after patients progress on first-line chemotherapy.

Radioembolization technique

Various practice guidelines and recommendations have been published that provide details on the administration and optimization of TARE.[14,50–55] This section will summarize a brief overview of the process with illustrative case studies.

Once patients are determined to be eligible candidates for TARE, they typically undergo a series of standard preparatory steps.[56–58] Patients first undergo a hepatic angiogram to map out the patient's hepatic arterial anatomy, identify the vessels supplying the tumor, which can demonstrate anatomic variations in about 45% of patients,[59] and assess for extrahepatic perfusion. A detailed understanding of the patient's arterial anatomy is important to prevent non-target extrahepatic deposition of radioactive particles and damage to non-target tissues.[56] Furthermore, the angiogram can help select the optimal catheter position to maximize tumor treatment while minimizing non-involved liver damage.[58,60] During angiography, collateral and extrahepatic vessels can be embolized if needed.[57] Afterward,

99mTechnetium-macroaggregated albumin (Tc-MAA) imaging and scintigraphy are performed to identify the distribution of the beads and identify potential gastrointestinal, intrahepatic, and/or pulmonary shunts. Generally, elevated lung-shunt fraction (LSF) is considered to be greater than 20%[61] and the maximum tolerated dose to the lung is 30 gray (Gy) for a single treatment or 50 Gy for multiple treatments.[57] In addition to conventional angiography, cone-beam CT is used to more accurately define vascular anatomy and tissue perfusion, which also aids in dosimetry calculations.[62–65]

After assessment of extrahepatic shunting, TARE procedure is performed with delivery of either resin or glass microsphere to the target hepatic artery.[57] For resin 90Y radioembolization, a catheter is placed in the target hepatic artery supplying tumor distal to the arteries supplying the gastrointestinal system and in similar location of Tc-MAA administration. The microspheres are injected slowly at a rate of <0.3 mL/s to avoid reflux. Rather than blind infusion, intermittent fluoroscopic guidance should be utilized to confirm antegrade flow. In addition, 5% glucose solution reduces stasis and is recommended over sterile water to minimize patient discomfort. Contrast medium should be repeatedly injected through the left-hand port of the delivery set to ensure that the catheter is correctly placed with forward flow. Glass 90Y radioembolization involves the injection of fewer microspheres (approximately 1.2–8 million), and a small volume (approximately 20–60 mL). The actual infusion itself is done with a slow hand injection and free breathing. About 60 mL of normal saline solution is delivered, and the infusion takes about 5 min. Like with resin 90Y radioembolization, blind infusions are not recommended with 166Ho microsphere given the relatively high embolic load, and the catheter is placed in the target hepatic artery distal to the arteries supplying the gastrointestinal system and in similar location of Tc-MAA administration with a slow infusion rate of <0.3 mL/min. Contrast media can be used to ensure good catheter position and forward flow. The use of antireflux catheter can be used to improve tumor deposition and minimize non-target injury to normal liver and extrahepatic organs.

TARE can be delivered in a single treatment session or span multiple sessions, depending on the specific tumor(s) and location. The International Commission on Radiation Units and Measurements provides definitions for planning target volume (PTV), clinical target volume, and anisotropic margin that allows for patient- and procedure-specific geometric uncertainty.[66] The PTV may involve a segment, a lobe, or both lobes of the liver.[40] Targeting several tumors throughout the liver during a single session is defined as whole liver delivery; treating tumors in one lobe during a single session, followed by the other lobe in a separate session, is defined as sequential delivery; and targeting just one lobe is defined as lobar delivery.[58]

The type of TARE can be divided by the targeted area(s). Radiation segmentectomy (Figure 1) is the delivery of an ablative dose that is limited to ≤2 adjacent hepatic segments; radiation lobectomy is the delivery to the entire right or left lobe; and radiation sectorectomy is the delivery to specific parts of the liver that are determined by Couinaud's divisions, which involves a plane dependent on the portal veins separated by a plane arising from the left, middle, and right hepatic veins.[56,63]

Some patients with lobar disease who are not amendable to radiation segmentectomy or lobectomy because of extensive disease may undergo a palliative-intent lobar dose (Figure 2).

The aim is to slow down tumor progression with some degree of tolerable doses to functional tissue.[57]

Another TARE option is to treat the whole liver, which is typically done for diffuse disease localized across both hepatic lobes.[56] This technique can be done by either treating each lobe separately or treating both lobes simultaneously. The bilobar technique typically requires waiting at least 30 days for liver regeneration after the first lobe is treated and is associated with fewer adverse events.[19,56,67]

Follow-up

Early imaging follow-up can demonstrate hepatic parenchymal enhancement after TARE, which may mimic the treated malignancy.[68,69] As a result, imaging is recommended at around 6–8 weeks after treatment to evaluate the response. The type of post-treatment imaging also depends on the treatment modality. For 90Y radioembolization, 90Y positron emission tomography (PET) and single-photon emission computed tomography/computed tomography (SPECT/CT) are used to

Figure 1. ^{90}Y segmentectomy. (a) Axial CT shows solitary colorectal metastatic disease that is too large for successful ablation. (b) Angiogram reveals a larger disease burden than expected, affecting two segments. (c) CBCT obtained during angiogram and used to accurately calculate volumes for dose calculations. (d) SPECT/CT after Tc99-MAA administration. (e) Post ^{90}Y SPECT; a 200 Gy dose was calculated and delivered to segments 5 and 8 (resin). (f) Axial CT shows interval decrease in size of tumor post ^{90}Y.
CBCT, cone-beam CT; CT, computed tomography; SPECT, single-photon emission computed tomography; Tc-MAA, ^{99m}Technetium-macroaggregated albumin.

approximate ^{90}Y distribution and confirm tumor uptake, while for ^{166}Ho radioembolization, SPECT (ideally with additional low-dose CT) or magnetic resonance imaging (MRI) may be used.[57]

Challenges and complications of radioembolization

While shown to be effective and relatively safe, TARE has several limitations, including the heterogeneous distribution of the beads and radiation dose.[56] Radioembolization, especially to infiltrative lesions, is also susceptible to the crossfire phenomenon (i.e., nearby tissues acquire radiation from surrounding targeted regions) or to radiation-induced bystander effects (i.e., signal-mediated effects that arise in unirradiated cells within an irradiated region).[70]

Patients can experience various complications, such as post-radioembolization syndrome, which is similar to the post-embolization syndrome observed in patients receiving conventional TACE[71] but generally milder. There can be changes in hepatic volumes after TARE, possibly mediated by fibrosis and hepatic remodeling.[72,73]

These changes can lead to increases in portal pressures, such as splenomegaly.[72,74,75] Hepatic complications, such as hepatic abscesses[76] or radioembolization-induced liver disease, which is characterized by jaundice, and ascites, may also occur within 1–2 months after TARE without progression of disease or occlusion of the biliary ducts.[77] Patients can also develop delayed hepatotoxicity, especially if they have a tumor burden of greater than 50% and cirrhosis.[78] Biliary complications, such as biliary necrosis with biloma formation, may also arise.[79] Furthermore, patients may develop perihepatic fluid and pleural effusions, radiation pneumonitis, lymphopenia, gastrointestinal complications, as well as pulmonary complications via microscope shunting.[75,80,81] The overall incidence of these complications comprises a very small fraction of patients.

Radioembolization in the era of systemic therapies

Integrating TARE with systemic therapies presents numerous potential synergistic benefits for the treatment of primary and metastatic liver tumors, including enhancing the sensitivity of tumor cells to chemotherapy and triggering

Figure 2. [90]Y Lobar radioembolization. (a) Pre ^{90}Y radioembolization planar PET/CT demonstrates the extent of colorectal metastatic disease in the liver. (b) Pre-^{90}Y radioembolization axial fused PET/CT shows active metastasis in both lobes. (c) Axial fused SPECT Tc99-MAA shows delivery of Tc99-MAA particles in both lobes on mapping/shunt study. (d) Coronal planar SPECT study shows ^{90}Y delivery to the left hepatic lobe. (e and f) Axial fused SPECT post ^{90}Y demonstrates ^{90}Y delivery to the left hepatic lobe after the first session (e) and right hepatic lobe on the follow up session (f); 110 Gy dose delivered to the tumor. (g) 10-Month post-treatment PET/CT shows a good response (e.g., no hypermetabolic disease).
CT, computed tomography; PET, positron emission tomography; SPECT, single-photon emission computed tomography; Tc-MAA, [99m]Technetium-macroaggregated albumin.

heightened local and systemic immune responses when combined with immune checkpoint inhibitors (ICIs).[82] In this section, we explore the current evidence of TARE with systemic therapies in HCC, metastatic colorectal cancer to the liver, and intrahepatic cholangiocarcinoma.

Hepatocellular carcinoma
ICIs with a vascular endothelial-derived growth factor inhibitor (atezolizumab plus bevacizumab and tremelimumab plus durvalumab) have now become the new standard of care first-line therapy for unresectable HCC over sorafenib.[83–86] Despite limited studies, radioembolization is a promising candidate for synergy with immunotherapy and has shown to recruit and activate intra-tumor effector immune cells and overcome exhaustion.[82,87,88] A 2020 retrospective study investigated the safety of TARE with nivolumab or nivolumab plus ipilimumab in 26 patients with HCC and found no 30-day mortality or grades 3–4 hepatobiliary or immunotherapy-related toxicities. The median overall survival from first immunotherapy was 17.2 and 16.5 months from first TARE.[89] More recently, phase II NASIR-HCC was a single-arm trial to evaluate TARE followed by nivolumab in 42 patients who were naïve to immunotherapy and had unresectable HCC.[90] The study found only 8 patients had treatment-related adverse events and 5 had grade 3–4 serious adverse events. The objective response rate was 41.5%, and four patients were able to be downstaged to partial hepatectomy. The time to progression was 8.8 months, and the median overall survival was 20.9 months.[90] In another phase I/IIa trial, TARE followed by durvalumab for locally advanced unresectable HCC in 24 patients demonstrated a median time to progression of 15.2 months, an 18-month overall survival of 58.3%, median PFS of 6.9 months, and an objective response rate of 83.3%. The study found 11 (47.8%) any-grade treatment-related adverse events and 2 (8.7%) grade 3 treatment-related adverse events.[91] Finally, in a. open-label pilot study of 29 patients with poor prognosis HCC, combination pembrolizumab and TARE demonstrated a median PFS of 9.95 months, median overall survival of 27.3 months, objective response rate of 30.8%, disease control rate of 84.6%, and 48.1% had adverse events grade 3 or higher.[92]

Other studies investigating the role of TARE in the setting of systemic therapies for HCC have been recently conducted with promising findings. In a 2024 retrospective analysis of 44 patients with HCC who received TARE within

4 weeks of ICI or tyrosine kinase inhibitor (TKI) therapy, propensity score matching analysis showed that those receiving TARE and ICI had significantly greater objective response rates (89.5% vs 36.8%; $p < 0.001$) and disease control rates (94.7% vs 63.2%; $p < 0.001$) but no significant difference in median PFS and overall survival (OS).[93] A 2023 retrospective analysis of 19 patients with unresectable HCC who underwent concurrent atezolizumab/bevacizumab or nivolumab combination with TARE (10 with atezolizumab/bevacizumab and 9 with nivolumab) found an objective response rate of 58% (60% in nivolumab vs 56% in atezolizumab/bevacizumab; $p = 0.7$) and a complete response of 16% (10% vs 22%; $p = 0.8$).[94] The study also found a median OS of 12.9 months (16.4 months for nivolumab vs 10.7 months for atezolizumab/bevacizumab) and 0% grade $\geqslant 3$ adverse events in the nivolumab group and 11% in the atezolizumab/bevacizumab group.[94]

Intrahepatic cholangiocarcinoma

The landmark phase ABC-02 trial established cisplatin plus gemcitabine as the first-line for unresectable cholangiocarcinoma.[95] Currently, due to the results from the phase III TOPAZ-1 trial, the new first-line standard of care is gemcitabine, cisplatin, and durvalumab.[96] However, this regimen is still associated various Grade 3 and 4 adverse events.[97] The use of TARE has been increasing for intrahepatic cholangiocarcinomas due to its capacity to selectively administer high-dose radiation to the tumor. A single-arm phase II MISPHEC trial of 41 patients demonstrated the effective anti-tumor activity of gemcitabine and cisplatin plus TARE for the treatment of unresectable intrahepatic cholangiocarcinoma.[98] The median PFS was 14 months, the median overall survival was 22 months, and 9 (22%) patients were able to be downstaged to surgical intervention. However, the study had 29 (71%) grade 3–4 toxicities. A prospective, single-arm, open-label feasibility study was conducted on 24 chemotherapy-naïve patients with unresectable intrahepatic cholangiocarcinoma to evaluate the safety and effectiveness of TARE as first-line therapy without chemotherapy. The study found a median hepatic PFS of 5.5 months, median overall survival of 19.4 months (25.9 months in solitary disease and 10.7 months in multifocal disease), and 2 (8%) Grade 3 toxicities. Due to the previous findings of the potential synergism of radiation with capecitabine,[99–103] combination of

TARE plus cisplatin and gemcitabine was evaluated in a retrospective study of 13 patients with intrahepatic cholangiocarcinoma. The study showed a median overall survival of 29 months, 1-year overall survival of 84.6%, and 2-year survival of 52.9%. Furthermore, seven patients were downstaged to surgery and had a more favorable overall survival. In addition, a prospective, single-arm, open-label feasibility study was conducted on 24 chemotherapy-naïve patients with unresectable intrahepatic cholangiocarcinoma to evaluate the safety and effectiveness of TARE as first-line therapy without chemotherapy. The study found a median hepatic PFS of 5.5 months, a median OS of 19.4 months (25.9 months in solitary disease and 10.7 months in multifocal disease), and 2 (8%) Grade 3 toxicities.

More recently, a study analyzed data from patients with liver-only intrahepatic cholangiocarcinoma treated with chemotherapy alone from the ABC-01, ABC-02, ABC-03, BINGO, and AMEBICA trials and compared that to patients treated with TARE and chemotherapy in MISPHEC. The study found that after weighting, the combination arm had a significantly greater median OS (21.7 vs 15.9 months) and median PFS (14.3 vs 8.4 months) than the chemotherapy alone.[104]

Metastatic colorectal cancer

More literature is available for combination of systemic therapy with TARE in metastatic colorectal cancer compared with HCC. A phase III trial of 74 patients with bilobar non-resectable liver metastases from primary adenocarcinoma of the colon evaluated TARE plus floxuridine versus floxuridine alone[105] and found a significantly greater partial and complete response rate as well as median time to disease progression in the liver for patients receiving combination therapy. The combination arm was also associated with an upward trend toward increased survival after 15 months but was not statistically significant. Similar findings were seen in a small phase II trial of 21 patients with previously untreated advanced colorectal liver metastases who were randomized to TARE vs. TARE plus fluorouracil/leucovorin. Median OS was greater in the combination arm (29.4 vs 12.8 months) as well as grade 3–4 toxicity events.[106] Another phase III trial of 44 patients with unresectable, chemotherapy-refractory liver-limited metastatic colorectal cancer investigated TARE plus fluorouracil versus fluorouracil alone and showed a greater median time to liver

progression in the combination therapy arm (5.5 vs 2.1 months), greater median time to tumor progression (4.5 vs 2.1 months)[107] but no significant difference in observed in grade 3–4 toxicities. The SIRFLOX study, which combined the findings from three phase III trials[24–26]—FOXFIRE, SIRFLOX, and FOXFIRE-Global investigated the use of first-line radioembolization plus chemotherapy versus chemotherapy alone in patients with metastatic colorectal cancer to the liver.[27] In this study, 554 patients were randomly assigned to FOLFOX plus TARE and 549 patients to FOLFOX alone.[27] The study found no difference in overall survival but greater odds of a patient having a grade 3+ adverse event in the combination arm. Finally, the phase III EPOCH trial analyzed the combination of TARE with second-line systemic chemotherapy in 428 patients with colorectal liver metastases and found a longer PFS (median PFS 8.0 vs 7.2 months), hepatic PFS in the TARE plus chemotherapy arm when compared to the chemotherapy alone arm (median hepatic PFS 9.1 vs 7.2 months),[108] and higher objective response rates (34.0% vs 21.1%). However, there were more grade 3 adverse events in the TARE arm (68.4% vs 49.3%) and no difference in median OS.[108]

Neuroendocrine liver metastases

Neuroendocrine liver metastases are another area where radioembolization has a promising role. Several studies have shown that TARE of neuroendocrine liver metastases in the salvage setting is relatively efficacious and safe.[109–115] Several small studies have been conducted to analyze the combination of TARE with systemic treatments in neuroendocrine liver metastases.[116–118] Two retrospective studies compared TACE to radioembolization in patients with neuroendocrine liver metastases.[119,120] One showed that while TACE had a greater disease control rate, there were no differences in median overall survival or PFS.[119] The other study showed that patients treated with conventional TACE had a significantly greater median overall survival than those treated with DEB-TACE and TARE and a significantly greater hepatic PFS when compared to TARE.[120] Long-term outcomes of TARE in 107 patients with neuroendocrine liver metastasis in the RESiN liver tumor registry were analyzed, and showed 1-, 2-, and 3-year overall survival of 75%, 62%, and 46%, respectively, and the median overall survival was 33 months and highest in patients with pancreatic and hindgut primaries and lowest in foregut primaries. Thirteen (7.6%) patients had grade 3 hepatic toxicity, with ascites being the most common.[114] A recent study of 47 patients with neuroendocrine liver metastases who underwent TARE found that a pre-Tmean/Lmax > 1.9 and a SUVmax > 28 on ^{68}Ga-DOTATATE PET/CT were significant prognostic factors of longer overall survival and hepatic PFS.[121]

New developments in radioembolization

Holmium-166

Holmium-166 (^{166}Ho) is a neutron-activated isotope used as an alternative to ^{90}Y for radioembolization.[122] 166Ho microspheres received the Conformitè Europëenne (CE) mark in 2015 as QuiremSpheres™ (Quirem BV, Deventer, The Netherlands) for the management of unresectable liver tumors.[123,124] Furthermore, a scout dose of ^{166}Ho, which is used for the assessment of intra- and extrahepatic distribution of the injected microspheres before treatment, was also given CE mark in 2018 as QuiremScout™ (Quirem BV).[123,124]

Unlike ^{90}Y microspheres, ^{166}Ho microspheres emit both high-energy beta radiation for the treatment of tumors and gamma radiation, which can be utilized for nuclear imaging purposes. In addition, ^{166}Ho microspheres are also paramagnetic and can be visualized by MRI.[125–127] Following promising results from animal studies,[128–132] several prospective trials of ^{166}Ho in patients with HCC and unresectable and chemorefractory liver metastasis have shown to be safe and feasible.[118,127,133–136] Several trials are still ongoing and will further elucidate the safety and clinical application of ^{166}Ho treatment.

Eye90 microspheres

Although ^{90}Y PET and bremsstrahlung SPECT are used for post-treatment imaging, these techniques do not have sufficient spatial resolution to estimate the actual micro-distribution of ^{90}Y activity.[56,136,137] CT imaging could potentially provide better visualization of the dose distribution (e.g., reduced partial volume effects and faster scanning time), but one of its main limitations has been the lack of sufficient radiopacity required to be visualized.[137] Recently, a preclinical radiopaque microsphere, Eye90 microspheres™ (ABK Biomedical Inc., Halifax, NS,

Figure 3. Radioembolization using Eye90 microsphere. (a) Baseline MRI shows a focal HCC measuring 3.5×2.1 cm. (b) Post-procedure CT shows radiopacity of spheres in the tumor. (c) Post-SPECT CT of treated tumor with 0.8 GBq. (d) 3-Month post-treatment CE CT reveals no tumor enhancement. (e) 3-Month post-treatment CE MRI shows 1.3×1.5 cm density, corresponding to complete response by mRECIST criteria. (f–h) CT dosimetry with (i) corresponding dose color map legend. (j) SPECT with (k) corresponding dose color map legend. (l) SPECT CT shows proper deposition of Eye90 within the target tumor.
CE, Conformitè Europëenne; CT, computed tomography; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging.

Canada), has been developed and has the theoretical benefit of improved visibility with X-ray and CT imaging.[138] In a rabbit model, a preclinical study performed precision dosimetry with Eye90[137] and demonstrated that the CT-based method of post-TARE dosimetry had better visualization of the dose distribution, less partial volume effects, improved representation of dose heterogeneity, and less respiratory motion uncertainties. A clinical trial evaluating its safety, effectiveness, and impact on quality of life in patients with unresectable HCC or metastatic colorectal cancer is under investigation.[138] A sample case of Eye90 microspheres (Figure 3).

New dosimetry developments
There are three models used for dosimetry for TARE: the single-compartment model, the multi-compartment model, and the voxel-based model.[139,140] The single-compartment model treats the tumor and normal liver tissue together, and a mean dose is determined based on the perfused volume. Under this model, classical methods to prescribe radiation doses include the body surface area (BSA)-based and the medical internal radiation dose (MIRD) methods. The BSA-based method, which was historically used with resin microspheres, lacks the individualization of activity administration according to the actual liver and tumor volumes.[57] The single-compartment MIRD method, which is mostly used with glass microsphere, assumes a complete homogenous distribution of the microspheres in the perfused volume. This method determines the absorbed dose to a compartment based on the desired dose to the tumor regardless of tumor burden.[57]

The multi-compartment model calculates a mean dose by considering each compartment (the tumor, the normal liver, and the lung), aiming to maximize delivery to the tumor and minimize toxicity to surrounding tissue.[57] Unlike the BSA-based and MIRD single-compartment methods, the partition method follows the multi-compartment model and uses a tumor-to-normal (T/N) uptake ratio, which is considered more individualized and accurate. However, it requires Tc-MAA or similar microspheres that may have inconsistent distributions.[57] A major limitation of the multi-compartment model is the lack of an accurate surrogate and variabilities in perfusion; hence, there is no FDA approval.

Voxel-based dosimetry estimates dose gradients within each compartment instead of averaging over each compartment.[57,139] A voxel is a volumetric pixel defining a point in 3D space that is obtained through PET/CT, SPECT, or SPECT/CT. Several software systems have been created to convert the voxel's value into a radiation dose; therefore, voxel-based dosimetry has been shown to be more accurate than using mean absorbed dose.[141] Voxel-based dosimetry allows for improved personalization by having each voxel be a source and/or target for 3D visualization of absorbed dose distributions.[50] The idea of personalized dosimetry is gaining traction, especially after the DOSISPHERE-01 trial showed its higher response rate with a personalized than standard dosimetry.[142] Voxel-based dosimetry, as the top-tier personalized dosimetry approach, could be utilized for both segmentectomy and lobar treatment (Figure 4).

In a retrospective study, the different dosimetry approaches on the pre-treatment absorbed dose calculations based on ^{99m}Tc-MAA images were evaluated in 14 patients ($n = 101$ individual tumors). The mean absorbed dose among the various dosimetry methods was higher in tumor volumes than in non-tumor volumes. The study found that differences between the "Multi-tumor Partition Model," which considers each individual tumor a different compartment and allows for the calculation of mean absorbed doses within each individual tumor, and two 3D voxel dosimetry methods (dose-point kernel convolution and local deposition method (LDM)) was much lower than differences between the partition model and both 3D-voxel based dosimetry methods. Historically, many of the post-radioembolization images and dosimetry calculations were limited by in-house developed algorithms.[143] However, MIM SurePlan™ introduced a commercial software, LiverY90 (MIM Software, Inc., Cleveland, OH, USA), that received FDA approval (FDA 510(K) Number K172218) to convert ^{90}Y PET and/or SPECT images into dose maps to perform dosimetry.[143] This software allows for two algorithms, the Voxel S Value and the LDM, and studies have validated the software for clinical integration.[143,144]

Scout dose of Y90 for dosimetry

Low-dose/scout ^{90}Y microspheres have been proposed for pre-treatment planning and shunt study as ^{99m}Tc-MAA does not accurately predict shunting (Figure 5).

A recent prospective, single-arm clinical trial compared the accuracy and safety of scout dose resin ^{90}Y microspheres with ^{99m}Tc-MAA SPECT in 30 patients with HCC.[145] Compared to ^{99m}Tc-MAA, scout dose ^{90}Y had higher linear correlation with therapeutic ^{90}Y dose with regard to the ratio of tumor:normal tissue ($r = 0.53$ vs $r = 0.904$), LSF ($r = 0.76$ vs $r = 0.39$), and predicted mean tumor dose ($r = 0.900$ vs $r = 0.74$). There was also a stronger agreement between the scout dose ^{90}Y and the therapeutic ^{90}Y dose than with ^{99m}Tc-MAA with regard to tumor:normal ratio and LSF via descriptive Bland–Altman analysis. In the non-segmental cohort, ^{99m}Tc-MAA had no significant correlation with the predicted mean tumor dose ($r = 0.341$) and non-tumoral liver dose ($r = 0.441$) of the therapeutic ^{90}Y dose, but scout dose ^{90}Y was very strongly correlated with predicted mean tumor dose ($r = 0.93$) and non-tumoral liver dose ($r = 0.95$). In the segmental cohort, both ^{99m}Tc-MAA and scout dose ^{90}Y were significantly correlated with the predicted mean tumor dose and non-tumoral liver dose of the therapeutic ^{90}Y dose. These findings suggest that scout dose ^{90}Y may be superior in estimating the biodistribution of ^{90}Y microspheres, especially for non-segmental treatments. A current major limitation of resin scout dosimetry involves administering close to 40% of a standard BSA dose.

Radioembolization as neoadjuvant therapy

Recently, TARE has been used as a neoadjuvant therapy for otherwise unresectable hepatic tumors.[146] One of the major limitations with resecting hepatic tumors is insufficient future

Figure 4. Voxel base dosimetry. A 65-year-old female with a history of prior malignancy presenting with unresectable newly diagnosed biopsy-proven right liver hepatocellular carcinoma. (a) MRI shows arterially enhancing mass on post-contrast T1 weighted image (panel and (b) in room hybrid CT. (c) Arteriogram shows hypervascular mass supplied by right hepatic artery, followed by radioembolization using Flex-3 resin ^{90}Y microspheres (SIRTEX Medical, Woburn, MA, USA). (d–f) Post-^{90}Y administration SPECT-CT confirmed target embolization of the tumor with high uptake, and dosimetry demonstrated a mean and maximum tumor dose of about 500 and 1300 Gy, respectively. (g–i) Voxel-based dosimetry highlights the differential absorbed dose in the tumor displayed as a percentage of the maximum tumor dose (displayed using rainbow colors) with highest absorbed dose in the tumor center compared to the lowest in the margin.
CT, computed tomography; MRI, magnetic resonance imaging.

liver remnant, which can lead to post-hepatectomy liver failure.[147] However, since lobar radioembolization can increase future liver remnants, new efforts are starting to use TARE prior surgery. A recent single center retrospective analysis analyzed 26 patients (16 with primary and 10 with metastatic disease) who underwent neoadjuvant lobar TARE followed by hepatectomy.[147] The study did not find grade IV morbidities or 90-day mortalities. Only one (3.8%) patient experienced post hepatectomy liver failure, which is lower than the average rate of 7.6% after hepatectomy.[148] The median survival of the study cohort was 28.9 months from surgery and 37.6 months from TARE. In the multi-center, retrospective LEGACY study that assessed ^{90}Y

radioembolization in 162 patients with solitary unresectable HCC ≤8 cm, 11 (6.8%) patients had TARE prior to resection and 34 (21.0%) prior to transplantation.[22] The study found that the patients who underwent radioembolization prior to resection or liver transplant had an overall survival of 100% (95% confidence interval (CI): 100%−100%) at 24 months and 92.8% (95% CI: 74.2%−98.2%) at 36 months.

^{90}Y radioembolization is also increasingly used in combination with immunotherapy for patients with HCC. Results from the phase II trial (CA 209-678) examined ^{90}Y radioembolization followed by nivolumab in 36 patients with advanced HCC.[149] The trial found a complete

Figure 5. Scout dosimetry using a small dose of resin rather than Tc-MAA. A patient with a 4.5 cm HCC. (a–c) Therapeutic ^{90}Y administration of 30 mCi with corresponding (a) fusion, (b) PET, and (c) CT. (d–f) Scout ^{90}Y dose of 15 mCi. (g–i) Tc99-MAA administration of 2 mCi.
CT, computed tomography; HCC, hepatocellular carcinoma; PET, positron emission tomography; Tc-MAA, [99m]Technetium-macroaggregated albumin.

response in 1 (3%) patient, a partial response in 10 (28%) patients, and an overall objective response rate of 30.6% (95% CI: 16.4%−48.1%). Only two (6%) patients had a grade III/IV treatment-related adverse event, and five (14%) patients had a treatment-related serious adverse event. The response rate from this study is comparable with the 41.5% response rate reported from the findings of the phase II NASIR-HCC trial.[90] In a retrospective case series, the safety and efficacy of combined ^{90}Y radioembolization and immunotherapy in 11 patients with unresectable liver metastases from uveal melanoma was assessed.[151] The study found a median hepatic PFS of 15.0 months (95% CI: 5.9–24.1 months) and an overall survival of 17.0 months (95% CI: 1.8–32.2 months) from the start of TARE. The study also found that one (9.1%) patient experienced a complete response, two (18.2%) patients with partial response, four (36.4%) patients with stable disease, and four (36.4%) patients with progressive disease.

New indications for here have been several studies comparing radioembolization

Prostate tumors

Cutting-edge applications of TARE outside the liver are starting to be developed. One such application has been for the treatment of prostate cancer. Prostate cancer is currently the second most common cancer in men in the United States with an estimated 268,490 new cases and about 34,500 deaths in 2022.[151] The benefits of TARE for prostate cancer is radiation's efficacy for prostatic lesions while minimizing some of its off-target effects and the short penetration of beta radiation compared to standard radiation sources like X-rays that have higher penetrations. While still at a very early stage, TARE to the prostate is currently being tested on animal models. A recent study investigated the use of ^{90}Y radioembolization to the prostatic artery in 14 male castrated beagles who were induced to have prostatic hyperplasia.[152] Each dog had ^{90}Y radioembolization to one of their prostatic hemigland with the

other as control. The study found that all dogs underwent successful ^{90}Y radioembolization with localization and coverage only to the treated hemigland, and a dose-dependent decrease in the treated hemigland size was observed at 40 days (25%−60%, $p < 0.001$). There were no adverse events or radiographic or TARE-related histologic extraprostatic changes. These early findings demonstrate that the technique is safe, feasible, and effective in canine models and sets the stage for future clinical investigations.

Brain tumors

Another potential application of ^{90}Y radioembolization is for the treatment of brain tumors. In a preclinical proof-of-concept and safety analysis,[153] eight dogs (five with spontaneous intra-axial brain masses and three controls) underwent ^{90}Y radioembolization of their cerebral artery. A month after the procedure, there was a 24%−94% reduction in mass volume, and a partial response in three (60%) of the dogs was observed at 6-month follow-up. Six (75%) dogs had developed acute neurologic deficits after the procedure, but these deficits resolved within 7–33 days after the procedure. Another study evaluated a patient-specific pipeline, previously used to estimate ^{90}Y dose distribution and absorption for liver cancer, called CFDose to predict dosimetry for TARE of brain cancer.[154] This novel approach segments the vascular network of patients from imaging, analyzes their blood flow behavior, and calculates the absorbed dose distribution by convolving the predicted distribution with a point kernel. In this proof-of-concept study, CFDose was tested in a head CT angiogram of a patient with no brain cancer. Future investigations in patients with brain cancer will likely provide more insight on the feasibility of CFDose or similar personalized dosimetry models.

Lung tumors

While still at an early stage, lung tumors may be a potential target for TARE. A case report in 2013 describes the use of ^{90}Y radioembolization via bronchial arteries in a patient with metastatic colorectal cancer and in another with metastatic renal cell cancer with promising results (e.g., stable disease or partial remission in the treated lesions).[155] Furthermore, in a recent abstract, eight patients with primary or metastatic lung tumors who were going to get bronchial artery embolization for hemoptysis were administered Tc99m-MAA via the bronchial artery immediately prior to bland embolization to assess the anticipated dose to tumor and organs at risk if they were to have received ^{90}Y radioembolization.[156] Investigators found tumor mean dose and biological effective doses would range from 175 to 2928 Gy with a mean of 813 Gy while satisfying dosimetry constraints to organs at risk.

Artificial intelligence

Artificial intelligence has been transforming the approach to dosimetry by reducing the labor- and time-intensive aspects of segmentation of target and organ at risks. A recent study found that convolutional neural network (CNN)-based algorithms can automatically segment lung, liver, and tumors on ^{99m}Tc-MAA SPECT/CT images for ^{90}Y radioembolization planning.[157] The study found that the overall segmentation took approximately 1 min per patient on a consumer-level computer system, and the dosimetry parameters for the three CNN-based segmentation algorithms were comparable to that of reference segmentations by physicians. Artificial intelligence has also been shown to predict treatment response to TARE. In a retrospective single-center radiomics analysis comprising 36 patients with 104 liver metastases who underwent cone-beam computed tomography before TARE, a custom artificial neural network had a sensitivity of 94.2% and specificity of 67.7% (The area under curve = 0.85), after dimension reduction (15 of 104 remained for the analysis), for predicting treatment response.[159] In another retrospective study, a machine learning technique was used to predict individual risk from baseline pre-therapeutic factors in 366 patients with primary ($n = 92$) or secondary ($n = 274$) hepatic tumors who underwent ^{90}Y radioembolization.[159] The study identified baseline cholinesterase and bilirubin as the most important factors (forest-averaged lowest minimal depth 1.2 and 1.5, respectively), while sex was the least important (5.5) factor. A retrospective study developed a deep neural network to predict the treatment response in 77 patients with 103 lesions with HCC who underwent ^{90}Y radioembolization.[160] The study found that their model had a higher F1-score, accuracy, and sensitivity at predicting complete treatment response when compared to the voxel-based dosimetry model. Another analysis utilized machine learning and machine vision image analysis to predict modified Response Evaluation

Criteria in Solid Tumors treatment response from preprocedural imaging in 30 patients treated with TARE for HCC and found an area under the receiver operating characteristic curve of 0.626 ± 0.17 with an improvement to 0.858 ± 0.114 with support vector machine models.[161]

Conclusion

Radioembolization is a valuable and increasingly utilized therapeutic option for the management of patients with primary and metastatic liver tumors. While initially offered as a palliative option for the treatment of hepatic tumors, radioembolization has expanded over the years to its inclusion as an option with curative intent. Nonetheless, a multi-disciplinary approach is required to select the appropriate patients to maximize outcomes. Growing advances in radioembolization and its dosimetry continue to expand the treatment options for patients with liver tumors. Novel indications for radioembolization are emerging and offer a promising treatment for future research and clinical applications.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Author contributions
Arian Mansur: Conceptualization; Methodology; Visualization; Writing – original draft; Writing – review & editing.

Peiman Habibollahi: Investigation; Writing – review & editing.

Adam Fang: Investigation; Writing – review & editing.

Armeen Mahvash: Investigation; Writing – review & editing.

Vahid Etezadi: Investigation; Writing – review & editing.

Robert P. Liddell: Investigation; Writing – review & editing.

Juan C. Camacho: Investigation; Writing – review & editing.

Emil I. Cohen: Investigation; Writing – review & editing.

Nima Kokabi: Investigation; Visualization; Writing – review & editing.

Aravind Arepally: Investigation; Visualization; Writing – review & editing.

Christos Georgiades: Investigation; Writing – review & editing.

Nariman Nezami: Conceptualization; Investigation; Methodology; Visualization; Writing – review & editing.

ORCID iD

Arian Mansur (iD) https://orcid.org/0000-0003-2406-5127

References

1. Bernier J, Hall EJ and Giaccia A. Radiation oncology: a century of achievements. *Nat Rev Cancer* 2004; 4: 737–747.

2. Baskar R, Dai J, Wenlong N, et al. Biological response of cancer cells to radiation treatment. *Front Mol Biosci* 2014; 1: 24.

3. Allison RR, Sibata C and Patel R. Future radiation therapy: photons, protons and particles. *Future Oncol* 2013; 9: 493–504.

4. National Cancer Institute. Radiation therapy to treat cancer, https://www.cancer.gov/about-

cancer/treatment/types/radiation-therapy (2019, accessed 14 August 2022).

5. American Cancer Society. The science behind radiation therapy, https://www.cancer.org/content/dam/CRC/PDF/Public/6151.00.pdf (2014, accessed 14 August 2022).

6. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; 334: 693–699.

7. Tsochatzis EA, Fatourou E, O'Beirne J, et al. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. *World J Gastroenterol* 2014; 20: 3069–3077.

8. Qadan M, Fong ZV, Delman AM, et al. Review of use of Y90 as a bridge to liver resection and transplantation in hepatocellular carcinoma. *J Gastrointest Surg* 2021; 25: 2690–2699.

9. Titano J, Voutsinas N and Kim E. The role of radioembolization in bridging and downstaging hepatocellular carcinoma to curative therapy. *Semin Nucl Med* 2019; 49: 189–196.

10. Lee EJ, Chung HW, Jo JH, et al. Radioembolization for the treatment of primary and metastatic liver cancers. *Nucl Med Mol Imaging* 2019; 53: 367–373.

11. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. *Radiology* 1988; 169: 311–314.

12. Wollner I, Knutsen C, Smith P, et al. Effects of hepatic arterial yttrium 90 glass microspheres in dogs. *Cancer* 1988; 61: 1336–1344.

13. Fabritius MP and Ricke J. Overview of ongoing clinical trials on radioembolization. *Cardiovasc Intervent Radiol* 2022; 45: 1659–1662.

14. Giammarile F, Bodei L, Chiesa C, et al. Therapy, Oncology and Dosimetry Committees. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. *Eur J Nucl Med Mol Imaging* 2011; 38: 1393–1406.

15. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. *Radiographics* 2005; 25(Suppl. 1): S41–S55.

16. Wang EA, Stein JP, Bellavia RJ, et al. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. *Int J Clin Pract* 2017; 71: 20170730.

17. Maciak M, Konior M, Wawszczak D, et al. Physical properties and biological impact of 90Y microspheres prepared by sol–gel method for liver radioembolization. *Radiat Phys Chem* 2023; 202: 110506.

18. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. *Eur Radiol* 2009; 19: 951–959.

19. Salem R and Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. *J Vasc Interv Radiol* 2006; 17: 1251–1278.

20. Iñarrairaegui M, Pardo F, Bilbao JI, et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. *Eur J Surg Oncol* 2012; 38: 594–601.

21. Cremonesi M, Chiesa C, Strigari L, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. *Front Oncol* 2014; 4: 210.

22. Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. *Hepatology* 2021; 74: 2342–2352.

23. Vouche M, Lewandowski RJ, Atassi R, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. *J Hepatol* 2013; 59: 1029–1036.

24. Dutton SJ, Kenealy N, Love SB, et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. *BMC Cancer* 2014; 14: 497.

25. Gibbs P, Gebski V, Van Buskirk M, et al. Selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. *BMC Cancer* 2014; 14: 897.

26. van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation

therapy in patients with metastatic colorectal cancer. *J Clin Oncol* 2016; 34: 1723–1731.

27. Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncol* 2017; 18: 1159–1171.

28. Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. *J Clin Oncol* 2018; 36: 1913–1921.

29. Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. *Lancet Oncol* 2017; 18: 1624–1636.

30. Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology* 2016; 151: 1155–1163.e2.

31. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology* 2011; 140: 497–507.e2.

32. Riaz A, Gabr A, Abouchaleh N, et al. Radioembolization for hepatocellular carcinoma: statistical confirmation of improved survival in responders by landmark analyses. *Hepatology* 2018; 67: 873–883.

33. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2019; 30: 871–873.

34. Dhondt E, Lambert B, Hermie L, et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. *Radiology* 2022; 303: 699–710.

35. National Comprehensive Cancer Network. Hepatobiliary cancers (Version 1.2022),https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf (2022, accessed 12 July 2022).

36. Chow R, Simone CB 2nd, Jairam MP, et al. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90

for local treatment of liver cancer—a systematic review and network meta-analysis of survival data. *Acta Oncol* 2022; 61: 484–494.

37. Ozen M and Patel RK. Ablation versus radiation segmentectomy for small liver tumors. *Semin Intervent Radiol* 2023; 40: 511–514.

38. Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. *Lancet Gastroenterol Hepatol* 2022; 7: P843–P850.

39. Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for large hepatocellular carcinoma. *Am J Surg* 2001; 181: 347–353.

40. Kim J, Kim JY, Lee JH, et al. Long-term outcomes of transarterial radioembolization for large single hepatocellular carcinoma: a comparison to resection. *J Nucl Med* 2022; 63: 1215–1222.

41. Joo I, Kim HC, Kim GM, et al. Imaging evaluation following 90Y radioembolization of liver tumors: what radiologists should know. *Korean J Radiol* 2018; 19: 209–222.

42. Spina JC, Hume I, Pelaez A, et al. Expected and unexpected imaging findings after 90Y transarterial radioembolization for liver tumors. *Radiographics* 2019; 39: 578–595.

43. Wang LM, Jani AR, Hill EJ, et al. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. *J Clin Pathol* 2013; 66: 205–211.

44. Ji JH, Park SH, Lee J, et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. *Cancer Chemother Pharmacol* 2013; 72: 223–230.

45. Liddell RP. 90Y transarterial radioembolization for metastatic colorectal cancer. *Radiology* 2022; 305: 237–238.

46. Briody H, Duong D, Yeoh SW, et al. Radioembolization for hepatocellular carcinoma-current evidence and patterns of utilization. *J Vasc Interv Radiol* 2023; 34(7): 1200–1213.

47. National Comprehensive Cancer Network. Colon cancer (Version 1.2022), https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (2022, accessed 12 July 2022).

48. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016; 27: 1386–1422.

49. Emmons EC, Bishay S, Du L, et al. Survival and toxicities after ⁹⁰Y transarterial radioembolization of metastatic colorectal cancer in the RESIN Registry. *Radiology* 2022; 305: 228–236.

50. Levillain H, Bagni O, Deroose CM, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. *Eur J Nucl Med Mol Imaging* 2021; 48: 1570–1584.

51. Chiesa C, Sjogreen-Gleisner K, Walrand S, et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for ⁹⁹ᵐTc-MAA pre- and ⁹⁰Y peri-therapy dosimetry in liver radioembolization with ⁹⁰Y microspheres. *EJNMMI Phys* 2021; 8: 77.

52. Arntz PJW, Deroose CM, Marcus C, et al. Joint EANM/SNMMI/IHPBA procedure guideline for [⁹⁹ᵐTc]Tc-mebrofenin hepatobiliary scintigraphy SPECT/CT in the quantitative assessment of the future liver remnant function. *HPB* (*Oxford*) 2023; 25: 1131–1144.

53. Hong K, Akinwande O, Bodei L, et al. ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies. *Brachytherapy* 2021; 20: 497–511.

54. Braat AJ, Smits ML, Braat MN, et al. ⁹⁰Y hepatic radioembolization: an update on current practice and recent developments. *J Nucl Med* 2015; 56: 1079–1087.

55. Busse NC, Al-Ghazi MSAL, Abi-Jaoudeh N, et al. AAPM medical physics practice guideline 14.a: Yttrium-90 microsphere radioembolization. *J Appl Clin Med Phys* 2024; 25: e14157.

56. Kim SP, Cohalan C, Kopek N, et al. A guide to ⁹⁰Y radioembolization and its dosimetry. *Phys Med* 2019; 68: 132–145.

57. Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. *Eur J Nucl Med Mol Imaging* 2022; 49: 1682–1699.

58. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys* 2007; 68: 13–23.

59. Michels NA. Newer anatomy of the liver and its variant blood supply and collateral circulation. *Am J Surg* 1966; 112: 337–347.

60. Dezarn WA, Cessna JT, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰Y microsphere brachytherapy in the treatment of hepatic malignancies. *Med Phys* 2011; 38: 4824–4845.

61. Downing T, Bennett P and Kouri B. Hepatic metastases therapy. In: Bennett P, Oza UD, Trout AT, et al. (eds) *Diagnostic imaging: nuclear medicine*. 2nd ed. Philadelphia: Elsevier, 2016, pp. 478–481.

62. Martin M, Hocquelet A, Debordeaux F, et al. Comparison of perfused volume segmentation between cone-beam CT and ⁹⁹ᵐTc-MAA SPECT/CT for treatment dosimetry before selective internal radiation therapy using ⁹⁰Y-glass microspheres. *Diagn Interv Imaging* 2021; 102: 45–52.

63. Villalobos A, Soliman MM, Majdalany BS, et al. Yttrium-90 radioembolization dosimetry: what trainees need to know. *Semin Intervent Radiol* 2020; 37: 543–554.

64. Knight GM, Gordon AC, Gates V, et al. Evolution of personalized dosimetry for radioembolization of hepatocellular carcinoma. *J Vasc Interv Radiol* 2023; 34: 1214–1225.

65. Stein SI, Soliman MM, Sparapani J, et al. Conventional hepatic volumetry may lead to inaccurate segmental Yttrium-90 radiation dosimetry. *Cardiovasc Intervent Radiol* 2021; 44: 1973–1985.

66. Prescribing, recording, and reporting electron beam therapy. *J ICRU* 2004; 4: 2.

67. Seidensticker R, Seidensticker M, Damm R, et al. Hepatic toxicity after radioembolization of the liver using ⁹⁰Y-microspheres: sequential lobar versus whole liver approach. *Cardiovasc Intervent Radiol* 2012; 35: 1109–1118.

68. Maas M, Beets-Tan R, Gaubert JY, et al. Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice. *Insights Imaging* 2020; 11: 83.

69. Garg T, Shrigiriwar A, Habibollahi P, et al. Intraarterial therapies for the management of hepatocellular carcinoma. *Cancers* (*Basel*) 2022; 14: 3351.

70. Blyth BJ and Sykes PJ. Radiation-induced bystander effects: what are they, and how relevant are they to human radiation exposures? *Radiat Res* 2011; 176: 139–157.

71. Riaz A, Awais R and Salem R. Side effects of yttrium-90 radioembolization. *Front Oncol* 2014; 4: 198.

72. Jakobs TF, Saleem S, Atassi B, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. *Dig Dis Sci* 2008; 53: 2556–2563.

73. Singh P and Anil G. Yttrium-90 radioembolization of liver tumors: what do the images tell us? *Cancer Imaging* 2014; 13: 645–657.

74. Son MH, Ha LN, Bang MH, et al. Diagnostic and prognostic value of 99mTc-MAA SPECT/CT for treatment planning of 90Y-resin microsphere radioembolization for hepatocellular carcinoma: comparison with planar image. *Sci Rep* 2021; 11: 3207.

75. Alem Z, Murray TE, Egri C, et al. Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma. *Abdom Radiol* (*NY*) 2021; 46: 3596–3614.

76. Mascarenhas N, Ryu RK and Salem R. Hepatic radioembolization complicated by abscess. *Semin Intervent Radiol* 2011; 28: 222–225.

77. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. *Hepatology* 2013; 57: 1078–1087.

78. Currie BM, Hoteit MA, Ben-Josef E, et al. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. *J Vasc Interv Radiol* 2019; 30: 1915–1923.

79. Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. *J Vasc Interv Radiol* 2008; 19: 691–697.

80. Carr BI and Metes DM. Peripheral blood lymphocyte depletion after hepatic arterial 90Yttrium microsphere therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2012; 82: 1179–1184.

81. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. *Int J Radiat Oncol Biol Phys* 1995; 33: 919–924.

82. Mabud TS and Hickey R. Radioembolization in the setting of systemic therapies. *Semin Intervent Radiol* 2021; 38: 472–478.

83. Pinter M, Scheiner B and Pinato DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. *Lancet Gastroenterol Hepatol* 2023; 8: 760–770.

84. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. *J Hepatol* 2022; 76: 681–693.

85. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med* 2020; 382: 1894–1905.

86. Kudo M. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. *Hepatobiliary Surg Nutr* 2022; 11: 592–596.

87. Chew V, Lee YH, Pan L, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. *Gut* 2019; 68: 335–346.

88. Craciun L, de Wind R, Demetter P, et al. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. *BMC Cancer* 2020; 20: 135.

89. Zhan C, Ruohoniemi D, Shanbhogue KP, et al. Safety of combined Yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. *J Vasc Interv Radiol* 2020; 31: 25–34.

90. de la Torre-Aláez M, Matilla A, Varela M, et al. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. *J Immunother Cancer* 2022; 10: e005457.

91. Lee YB, Nam JY, Cho EJ, et al. A phase I/IIa trial of Yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma. *Clin Cancer Res* 2023; 29: 3650–3658.

92. Yu S, Yu M, Keane B, et al. A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma. *Oncologist* 2024; 29: 270-e413.

93. Garcia-Reyes K, Gottlieb RA, Menon KM, et al. Radioembolization plus immune checkpoint inhibitor therapy compared with radioembolization plus tyrosine kinase inhibitor therapy for the treatment of hepatocellular carcinoma. *J Vasc Interv Radiol* 2024; 35: 722–730.e1.

94. Villalobos A, Dabbous HH, Little O, et al. Safety and efficacy of concurrent atezolizumab/bevacizumab or nivolumab combination therapy with Yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma. *Curr Oncol* 2023; 30: 10100–10110.

95. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010; 362: 1273–1281.

96. Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. *Lancet Gastroenterol Hepatol* 2022; 7: 522–532.

97. Rimini M, Fornaro L, Lonardi S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. *Liver Int* 2023; 43: 1803–1812.

98. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. *JAMA Oncol* 2020; 6: 51–59.

99. Hickey R, Mulcahy MF, Lewandowski RJ, et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. *Int J Radiat Oncol Biol Phys* 2014; 88: 1025–1031.

100. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. *Lancet Oncol* 2012; 13: 579–588.

101. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. *Clin Cancer Res* 1999; 5: 2948–2953.

102. Saelen MG, Ree AH, Kristian A, et al. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. *Radiat Oncol* 2012; 7: 165.

103. Ahmed O, Yu Q, Patel M, et al. Yttrium-90 radioembolization and concomitant systemic gemcitabine, cisplatin, and capecitabine as the first-line therapy for locally advanced intrahepatic cholangiocarcinoma. *J Vasc Interv Radiol* 2023; 34: 702–709.

104. Edeline J, Bridgewater J, Campillo-Gimenez B, et al. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials. *Hepatology* 2024; 79: 96–106.

105. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Ann Oncol* 2001; 12: 1711–1720.

106. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. *J Surg Oncol* 2004; 88: 78–85.

107. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol* 2010; 28: 3687–3694.

108. Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. *J Clin Oncol* 2021; 39: 3897–3907.

109. Devcic Z, Rosenberg J, Braat AJ, et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. *J Nucl Med* 2014; 55: 1404–1410.

110. Peker A, Çiçek O, Soydal Ç, et al. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. *Diagn Interv Radiol* 2015; 21: 54–59.

111. Barbier CE, Garske-Román U, Sandström M, et al. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. *Eur J Nucl Med Mol Imaging* 2016; 43: 1425–1431.

112. Braat A, Kappadath SC, Ahmadzadehfar H, et al. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. *Cardiovasc Intervent Radiol* 2019; 42: 413–425.

113. Schaarschmidt BM, Wildgruber M, Kloeckner R, et al. 90Y radioembolization in the treatment of neuroendocrine neoplasms: results of an international multicenter retrospective study. *J Nucl Med* 2022; 63: 679–685.

114. Wong TY, Zhang KS, Gandhi RT, et al. Long-term outcomes following 90Y radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. *BMC Cancer* 2022; 22: 224.

115. Ramdhani K and Braat A. The evolving role of radioembolization in the treatment of neuroendocrine liver metastases. *Cancers* (*Basel*) 2022; 14: 3415.

116. Soulen MC, van Houten D, Teitelbaum UR, et al. Safety and feasibility of integrating Yttrium-90 radioembolization with capecitabine–temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors. *Pancreas* 2018; 47: 980–984.

117. Kim HS, Shaib WL, Zhang C, et al. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. *Cancer* 2018; 124: 1992–2000.

118. Braat A, Bruijnen RCG, van Rooij R, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. *Lancet Oncol* 2020; 21: 561–570.

119. Egger ME, Armstrong E, Martin RC 2nd, et al. Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis. *J Am Coll Surg* 2020; 230: 363–370.

120. Do Minh D, Chapiro J, Gorodetski B, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. *Eur Radiol* 2017; 27: 4995–5005.

121. Ingenerf M, Grawe F, Winkelmann M, et al. Neuroendocrine liver metastases treated using transarterial radioembolization: identification of prognostic parameters at 68Ga-DOTATATE PET/CT. *Diagn Interv Imaging* 2024; 105: 15–25.

122. Mumper RJ, Ryo UY and Jay M. Neutron-activated holmium-166-poly (L-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumors. *J Nucl Med* 1991; 32: 2139–2143.

123. Reinders MTM, Smits MLJ, van Roekel C, et al. Holmium-166 microsphere radioembolization of hepatic malignancies. *Semin Nucl Med* 2019; 49: 237–243.

124. Stella M, Braat A, van Rooij R, et al. Holmium-166 radioembolization: current status and future prospective. *Cardiovasc Intervent Radiol* 2022; 45: 1634–1645.

125. Nijsen JF, Seppenwoolde JH, Havenith T, et al. Liver tumors: MR imaging of radioactive holmium microspheres—phantom and rabbit study. *Radiology* 2004; 231: 491–499.

126. de Wit TC, Xiao J, Nijsen JF, et al. Hybrid scatter correction applied to quantitative holmium-166 SPECT. *Phys Med Biol* 2006; 51: 4773–4787.

127. Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. *Lancet Oncol* 2012; 13: 1025–1034.

128. Zielhuis SW, Nijsen JF, Krijger GC, et al. Holmium-loaded poly(L-lactic acid) microspheres: in vitro degradation study. *Biomacromolecules* 2006; 7: 2217–2223.

129. Nijsen F, Rook D, Brandt C, et al. Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. *Eur J Nucl Med* 2001; 28: 743–749.

130. Vente MA, Nijsen JF, de Wit TC, et al. Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs. *Eur J Nucl Med Mol Imaging* 2008; 35: 1259–1271.

131. Zielhuis SW, Nijsen JF, Seppenwoolde JH, et al. Long-term toxicity of holmium-loaded poly(L-lactic acid) microspheres in rats. *Biomaterials* 2007; 28: 4591–4599.

132. Turner JH, Claringbold PG, Klemp PF, et al. 166Ho-microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig. *Nucl Med Commun* 1994; 15: 545–553.

133. Prince JF, van den Bosch M, Nijsen JFW, et al. Efficacy of radioembolization with [166]Ho-microspheres in salvage patients with liver metastases: a phase 2 study. *J Nucl Med* 2018; 59: 582–588.

134. van Roekel C, van den Hoven AF, Bastiaannet R, et al. Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization—a prospective, within-patient randomized study. *Eur J Nucl Med Mol Imaging* 2021; 48: 1658–1668.

135. Reinders MTM, van Erpecum KJ, Smits MLJ, et al. Safety and efficacy of holmium-166 radioembolization in hepatocellular carcinoma—the HEPAR primary study. *J Nucl Med* 2022; 63: 1891–1898.

136. Roosen J, Westlund Gotby LEL, Arntz MJ, et al. Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery. *Eur J Nucl Med Mol Imaging* 2022; 49: 4705–4715.

137. Henry EC, Strugari M, Mawko G, et al. Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model. *EJNMMI Phys* 2022; 9: 21.

138. ABK Biomedical. Safety and effectiveness of Eye90 Microspheres™ in the treatment of unresectable HCC and mCRC, https://ctv.veeva.com/study/safety-and-effectiveness-of-eye90-microspheres-in-the-treatment-of-unresectable-hcc-and-mcrc (accessed 14 August 2022).

139. Bastiaannet R, Kappadath SC, Kunnen B, et al. The physics of radioembolization. *EJNMMI Phys* 2018; 5: 22.

140. Toskich BB and Liu DM. Y90 radioembolization dosimetry: concepts for the interventional radiologist. *Tech Vasc Interv Radiol* 2019; 22: 100–111.

141. Chiesa C, Bardiès M and Zaidi H. Voxel-based dosimetry is superior to mean absorbed dose approach for establishing dose–effect relationship in targeted radionuclide therapy. *Med Phys* 2019; 46: 5403–5406.

142. Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. *Lancet Gastroenterol Hepatol* 2021; 6: 17–29.

143. Maughan NM, Garcia-Ramirez J, Arpidone M, et al. Validation of post-treatment PET-based dosimetry software for hepatic radioembolization of Yttrium-90 microspheres. *Med Phys* 2019; 46: 2394–2402.

144. Guerrero M, Yao W, Lin M, et al. Validation of a commercial software dose calculation for Y-90 microspheres. *Brachytherapy* 2022; 21: 561–566.

145. Kokabi N, Webster LA, Elsayed M, et al. Accuracy and safety of scout dose resin Yttrium-90 microspheres for radioembolization therapy treatment planning: a prospective single-arm clinical trial. *J Vasc Interv Radiol* 2022; 33: 1578–1587.e5.

146. Carvalho VO, Galastri FL, Affonso BB, et al. Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports. *Einstein* (*Sao Paulo*) 2020; 18: eRC4990.

147. Ahmed A, Stauffer JA, LeGout JD, et al. The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure. *J Gastrointest Oncol* 2021; 12: 751–761.

148. Vibert E, Pittau G, Gelli M, et al. Actual incidence and long-term consequences of posthepatectomy liver failure after hepatectomy for colorectal liver metastases. *Surgery* 2014; 155: 94–105.

149. Tai D, Loke K, Gogna A, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. *Lancet Gastroenterol Hepatol* 2021; 6: 1025–1035.

150. Zheng J, Irani Z, Lawrence D, et al. Combined effects of Yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series. *J Vasc Interv Radiol* 2018; 29: 1369–1375.

151. American Cancer Society. Key statistics for prostate cancer, https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html (2022, accessed 29 October 2022).

152. Mouli SK, Raiter S, Harris K, et al. Yttrium-90 radioembolization to the prostate gland: proof of concept in a canine model and clinical translation. *J Vasc Interv Radiol* 2021; 32: 1103–1112.e12.

153. Pasciak AS, Manupipatpong S, Hui FK, et al. Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model. *EJNMMI Res* 2020; 10: 96.

154. Taebi A, Costa GCA and Roncali E. Personalized dosimetry for brain cancer radioembolization: a feasibility study. *J Nucl Med* 2021; 62: 1582.

155. Ricke J, Großer O and Amthauer H. Y90-radioembolization of lung metastases via the bronchial artery: a report of 2 cases. *Cardiovasc Intervent Radiol* 2013; 36: 1664–1669.

156. Wehrenberg-Klee E, An T, Heidari P, et al. Abstract No. 19 ▪ FEATURED ABSTRACT bronchial artery Tc99m-MAA injection in patients with pulmonary malignancies demonstrates future treatment potential of bronchial Y90 radioembolization. *J Vasc Interv Radiol* 2024; 35: S10.

157. Chaichana A, Frey EC, Teyateeti A, et al. Automated segmentation of lung, liver, and liver tumors from Tc-99m MAA SPECT/CT images for Y-90 radioembolization using convolutional neural networks. *Med Phys* 2021; 48: 7877–7890.

158. Kobe A, Zgraggen J, Messmer F, et al. Prediction of treatment response to transarterial radioembolization of liver metastases: radiomics analysis of pre-treatment cone-beam CT: a proof of concept study. *Eur J Radiol Open* 2021; 8: 100375.

159. Ingrisch M, Schöppe F, Paprottka K, et al. Prediction of ⁹⁰Y radioembolization outcome from pretherapeutic factors with random survival forests. *J Nucl Med* 2018; 59: 769–773.

160. Wagstaff WV, Villalobos A, Gichoya J, et al. Using deep learning to predict treatment response in patients with hepatocellular carcinoma treated with Y90 radiation segmentectomy. *J Digit Imaging* 2023; 36: 1180–1188.

161. Arndt S, Sandow T, Milburn J, et al. 3:00 PM Abstract No. 181 Machine learning and machine vision image analysis can predict treatment response from preprocedural imaging alone for Y90 radioembolization and DEB-TACE in hepatocellular carcinoma. *J Vasc Interv Radiol* 2018; 29: S79–S80.